GSK plc vs TJX Companies Inc — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while TJX Companies Inc trades at $138.86 (market cap $152.62B). The key difference: TJX Companies Inc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and TJX Companies Inc for 97 Days on average.
| GSK | TJX | |
|---|---|---|
Market Cap | $91.88B | $152.62B |
Volume | 7,730,529 | 8,079,794 |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $168.41 |
52-Week Low | $43.24 | $122.84 |
Typical Hold Time | 93 Days | 97 Days |
Enterprise Value | $111.88B | $160.93B |
Dividend Yield | 3.9% | 1.38% |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
TJX trades at $138.76, down slightly by 0.03% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals, with revenue rising to $56.36B in 2025 and net income reaching $4.86B, alongside robust profitability metrics like a 62.17% ROE. Recent quarterly earnings have consistently beaten expectations, and the firm maintains a solid balance sheet with manageable debt levels.
The outlook for TJX is positive, supported by Wall Street's strong buy consensus (84.9% buy ratings) and a $174.15 price target implying 28% upside. Key risks include competitive pressures in off-price retail and sensitivity to consumer spending trends. Investor sentiment is buoyed by earnings momentum and expansion potential, though overbought technical conditions may prompt near-term volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →